Staff Writer | Authors


FDA Approves Second-Line Axi-Cel for Adults With LBCL

April 01, 2022

The FDA has granted approval to axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy, according to an announcement from the FDA.

Targeted Therapy Is Considered a Necessity for Metastatic GIST

March 23, 2022

Targeted therapy with tyrosine kinase inhibitors is necessary after surgery for patients with metastatic gastrointestinal stromal tumors with residual disease requiring resection to prevent disease recurrence.